Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03636477
Recruitment Status : Recruiting
First Posted : August 17, 2018
Last Update Posted : March 22, 2019
Sponsor:
Information provided by (Responsible Party):
Ziopharm

Brief Summary:

This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.

Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (Nivolumab) is currently FDA approved in the United States for melanoma (a type of skin cancer), non-small cell lung cancer, renal cell cancer (a type of kidney cancer), Hodgkin's lymphoma but is not approved in glioblastoma. Nivolumab may help your immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in combination with Nivolumab to enhance the IL-12 mediated effect observed to date.

The main purpose of this substudy is to evaluate the safety and tolerability of a single tumoral injection of Ad-RTS-hIL-12 given with oral veledimex in combination with nivolumab.


Condition or disease Intervention/treatment Phase
Glioblastoma Biological: Ad-RTS-hIL-12 Drug: veledimex Drug: Nivolumab Phase 1

Detailed Description:

Eligible patients will receive one dose of nivolumab, via infusion, one week prior to standard of care craniotomy and tumor resection (subtotal or total). On the day of surgery, patients will receive one dose of veledimex before the resection procedure. Ad-RTS-hIL-12 will be administered by free-hand injection. Patients will continue on oral veledimex for 14 days. Following veledimex, patients will receive nivolumab via infusion every two weeks.

The study is divided into three periods: the screening period, the treatment period and the follow-up period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Protocol ATI001-102 Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Combination With Nivolumab in Subjects With Recurrent or Progressive Glioblastoma
Actual Study Start Date : June 18, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Ad-RTS-hIL-12 + veledimex in combination with nivolumab
Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
Biological: Ad-RTS-hIL-12
  • 2.0 x 10^11 viral particles (vp) per injection
  • intratumoral injection of Ad-RTS-hIL-12

Drug: veledimex
  • 2 doses (10mg/day, 20mg/day)
  • 15 oral daily doses of veledimex

Drug: Nivolumab
  • 2 doses (1mg/kg, 3mg/kg)
  • Every 2 weeks
Other Name: Opdivo




Primary Outcome Measures :
  1. Safety of intratumoral Ad-RTS-hIL-12 and oral veledimex doses in combination with nivolumab in subjects with recurrent or progressive glioblastoma. [ Time Frame: 3.5 years ]
    Evaluation of adverse events as assessed by CTCAE v4.03 will be based on the incidence, intensity and type of adverse event.

  2. Tolerability of intratumoral Ad-RTS-hIL-12 and oral veledimex doses in combination with nivolumab in subjects with recurrent or progressive glioblastoma. [ Time Frame: 3.5 years ]
    Evaluation will be based on expected dose compliance.


Secondary Outcome Measures :
  1. Optimal dose of Ad-RTS-hIL-12 and veledimex given in combination with nivolumab [ Time Frame: 3.5 years ]
  2. Tumor objective response rate (ORR) [ Time Frame: 3.5 years ]
  3. Progression free survival (PFS) [ Time Frame: 3.5 years ]
  4. Rate of pseudo-progression (PSP) [ Time Frame: 3.5 years ]
  5. Overall survival (OS) [ Time Frame: 3.5 years ]
  6. Changes from baseline in cellular responses elicited by Ad-RTS-hIL-12 and veledimex in combination with nivolumab. [ Time Frame: 3.5 years ]
  7. Changes from baseline in humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex in combination with nivolumab. [ Time Frame: 3.5 years ]
  8. Veledimex pharmacokinetic profile between the brain tumor and the blood. [ Time Frame: 3.5 years ]
    Evaluation: maximum plasma concentration (Cmax)

  9. Veledimex pharmacokinetic profile between the brain tumor and the blood. [ Time Frame: 3.5 years ]
    Evaluation: time to maximum plasma concentration (Tmax)

  10. Veledimex pharmacokinetic profile between the brain tumor and the blood. [ Time Frame: 3.5 years ]
    Evaluation: half-life (t1/2)

  11. Veledimex pharmacokinetic profile between the brain tumor and the blood. [ Time Frame: 3.5 years ]
    Evaluation: area-under-the-concentration versus time curve (AUC)

  12. Veledimex pharmacokinetic profile between the brain tumor and the blood. [ Time Frame: 3.5 years ]
    Evaluation: volume of distribution (Vd)

  13. Veledimex pharmacokinetic profile between the brain tumor and the blood. [ Time Frame: 3.5 years ]
    Evaluation: clearance (CL)

  14. Veledimex concentration ratio between the brain tumor and the blood. [ Time Frame: 3.5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subject ≥18 and ≤75 years of age
  • Provision of written informed consent for tumor resection, stereotactic surgery, tumor biopsy, samples collection, and treatment with investigational products prior to undergoing any study specific procedures
  • Histologically confirmed supratentorial glioblastoma
  • Evidence of tumor recurrence/progression by magnetic resonance imaging (MRI) according to response assessment in neuro-oncology (RANO) criteria after standard initial therapy
  • Previous standard-of-care antitumor treatment including surgery and/or biopsy and chemoradiation. At the time of registration, subjects must have recovered from the toxic effects of previous treatments as determined by the treating physician. The washout periods from prior therapies are intended as follows: (windows other than what is listed below should be allowed only after consultation with the Medical Monitor)

    1. Nitrosureas: 6 weeks
    2. Other cytotoxic agents: 4 weeks
    3. Antiangiogenic agents, including bevacizumab: 4weeks
    4. Targeted agents, including small molecule tyrosine kinase inhibitors: 2 weeks
    5. Vaccine-based therapy: 3 months
  • Able to undergo standard MRI scans with contrast agent before enrollment and after treatment
  • Karnofsky Performance Status ≥70%
  • Adequate bone marrow reserves and liver and kidney function, as assessed by the following laboratory requirements:

    1. Hemoglobin ≥9 g/L
    2. Lymphocytes >500/mm3
    3. Absolute neutrophil count ≥1500/mm3
    4. Platelets ≥100,000/mm3
    5. Serum creatinine ≤1.5 x upper limit of normal (ULN)
    6. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x ULN. For subjects with documented liver metastases, ALT and AST ≤5 x ULN
    7. Total bilirubin < 1.5 x ULN
    8. International normalized ratio (INR) and aPTT within normal institutional limits
  • Male and female subjects must agree to use a highly reliable method of birth control (expected failure rate <5% per year) from the Screening Visit through 28 days after the last dose of study drug. Women of childbearing potential (perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential) must have a negative pregnancy test at screening.
  • Normal cardiac and pulmonary function as evidenced by a normal ECG and peripheral oxygen saturation (SpO2) ≥90% by pulse oximetry

Exclusion Criteria:

  • Previous treatment with inhibitors of immunocheckpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody) or other agents specifically targeting T cells
  • Radiotherapy treatment within 4 weeks or less prior to veledimex dosing
  • Subjects with clinically significant increased intracranial pressure (eg, impending herniation or requirement for immediate palliative treatment) or uncontrolled seizures
  • Known immunosuppressive disease, or autoimmune conditions, and/or chronic viral infections (eg, human immunodeficiency virus [HIV], hepatitis)
  • Use of systemic antibacterial, antifungal, or antiviral medications for the treatment of acute clinically significant infection within 2 weeks of first veledimex dose. Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile prior to Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is allowed perioperatively.
  • Use of enzyme inducing antiepileptic drugs (EIAED) within 7 days prior to the first dose of study drug. Note: Levetiracetam (Keppra®) is not an EIAED and is allowed.
  • Other concurrent clinically active malignant disease, requiring treatment, with the exception of non-melanoma cancers of the skin or carcinoma in situ of the cervix or nonmetastatic prostate cancer
  • Nursing or pregnant females
  • Prior exposure to veledimex
  • Use of medications that induce, inhibit, or are substrates of cytochrome p450 (CYP450) 3A4 within 7 days prior to veledimex dosing without consultation with the Medical Monitor
  • Presence of any contraindication for a neurosurgical procedure
  • Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator or Medical Monitor, jeopardize the safety of a subject and/or their compliance with the protocol. Examples include, but are not limited to: unstable angina, congestive heart failure, myocardial infarction within 2 months of screening, ongoing maintenance therapy for life-threatening ventricular arrhythmia or uncontrolled asthma.
  • History of myocarditis or congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03636477


Contacts
Layout table for location contacts
Contact: Amy Smith 617-778-1241 asmith@ziopharm.com
Contact: Nathan Demars ndemars@ziopharm.com

Locations
Layout table for location information
United States, Illinois
Northwestern Memorial Hospital Recruiting
Chicago, Illinois, United States, 60611
United States, Massachusetts
Brigham & Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
Ziopharm
Investigators
Layout table for investigator information
Study Director: Arnold Gelb, MD Ziopharm Oncology, Inc.

Layout table for additonal information
Responsible Party: Ziopharm
ClinicalTrials.gov Identifier: NCT03636477     History of Changes
Other Study ID Numbers: ATI001-102 CPI Substudy 1.0
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: March 22, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents